News
The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback